GSK Earnings Prediction
The chart below shows how GSK performed 10 days before and after its earnings report, based on data from the past quarters. Typically, GSK sees a -0.37% change in stock price 10 days leading up to the earnings, and a +0.15% change 10 days following the report. On the earnings day itself, the stock moves by -0.52%. This data can give you a slight idea of what to expect for the next quarter's release.
GSK Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
10.42B
1.05%
4.74%
Gross Margin
71.01%
-2.15%
-3.92%
Operating Margin
29.28%
-7.90%
-0.51%
Net Margin
0.81%
-95.70%
-95.10%
EPS
-0.02
-104.44%
-105.56%
No Data Available
GSK Earnings Analysis
GSK plc American Depositary Shares (Each representing two Ordinary Shares) Corporation (GSK.N) Earnings Conference Call
Positive
Sales and Profit Growth: Despite some challenges, GSK reported a positive quarter with 9% sales growth and 19% profit growth year-to-date.
Quarterly Sales Growth: Sales for the quarter grew 2%, with 9% year-to-date growth, driven by a 19% increase in Specialty Medicines.
Core Profit and EPS Growth: Core operating profit and core EPS both grew 5%, reflecting the positive margin benefit of Specialty Medicines and sustained focus on cost management.
Operating Profit Increase: Year-to-date, operating profit was up 19%, supporting double-digit profit growth for the year.
Operational Cash Generation: Cash generated from operations was GBP 5.3 billion year-to-date, providing increased funds for pipeline investment and returns to shareholders.
Negative
Quarterly Sales Growth Analysis: Sales for the quarter grew only 2%, reflecting a tough comparison with strong growth from Specialty and General Medicines, offsetting lower sales of vaccines.
Operating Profit Decline: Operating profit decreased significantly year-on-year from GBP 1.9 billion last year to GBP 0.2 billion this year, primarily due to a GBP 1.8 billion charge related to the resolution of the Zantac litigation.
Profit Growth Decline: The decline in Gardasil royalties impacted profit growth by minus 8% this quarter, indicating underlying operating profit was only up 13%.
Operating Profit Challenges: Despite a 5% growth in core EPS, excluding COVID, the overall operating profit was significantly affected by the loss of royalties, leading to a challenging outlook for the year.
Vaccine Sales Decline: The overall sales decline of 15% for Vaccines was driven by lower demand for Shingrix and Arexvy, indicating a significant drop in market performance.
GSK FAQs
How does GSK typically perform around its earnings report dates?
Is GSK plc (GSK) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
GSK Earning Call Sentiment
GSK plc (GSK) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
GSK.N
3.57%Positive
The earnings call reveals mixed financial performance, with growth in Specialty Medicines and HIV sales but a decline in Vaccines. Despite a positive core operating margin and improved cash flow, the significant operating profit drop due to litigation is concerning. The Q&A session indicates management's confidence in long-term growth but lacks clarity on key product timelines and sales expectations. The dividend increase is a positive, but overall, the mixed signals and uncertainties lead to a neutral stock price prediction.